First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
Study Details
Study Description
Brief Summary
In the phase 1 portion of the study, the primary objectives are to assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a recommended phase 2 dose regimen (RP2DR) of REGN5459 as monotherapy in patients with relapsed or refractory multiple myeloma (MM) who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit.
In the phase 2 portion of the study, the primary objective is to assess the preliminary anti-tumor activity of REGN5459 as measured by objective response rate (ORR).
In the phase 1 and phase 2 portion, the secondary objectives of the study are:
-
To assess the preliminary anti-tumor activity of REGN5459 as measured by duration of response (DOR), progression-free survival (PFS), rate of minimal residual disease (MRD) negative status, and overall survival (OS)
-
To evaluate the pharmacokinetic (PK) properties of REGN5459
-
To characterize the immunogenicity of REGN5459
-
To evaluate the effects of REGN5459 on patient-reported quality of life (QoL), symptoms, functioning and general health status
In the phase 1 portion of the study only, the secondary objective of the study is to assess the preliminary anti-tumor activity of REGN5459 as measured by ORR.
In the phase 2 portion of the study only, the secondary objective of the study is to evaluate the safety and tolerability of REGN5459.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: REGN5459 Cohorts of multiple REGN5459 dose levels |
Drug: REGN5459
Administered by intravenous (IV) infusion
|
Outcome Measures
Primary Outcome Measures
- Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period [Up to 35 Days]
Phase 1
- Incidence and severity of treatment-emergent adverse events (TEAEs) during REGN5459 treatment period [Up to 12 Weeks After the Last Dose]
Phase 1
- Incidence and severity of adverse events of special interest (AESI) with REGN5459 treatment period [Up to 12 Weeks After the Last Dose]
Phase 1
- Objective response rate (ORR) as measured using the International Myeloma Working Group (IMWG) criteria [Up to Approximately 104 Weeks]
Phase 2
Secondary Outcome Measures
- Concentrations of REGN5459 in the serum over time [Up to 12 Weeks After the Last Dose]
Phase 1 and phase 2
- Incidence over time of anti-drug antibodies (ADAs) to REGN5459 [Up to 12 Weeks After the Last Dose]
Phase 1 and phase 2
- Duration of response (DOR) using the IMWG criteria [Up to Approximately 104 Weeks]
Phase 1 and phase 2
- Progression-free survival (PFS) as measured using the IMWG criteria [Up to Approximately 104 Weeks]
Phase 1 and phase 2
- Rate of minimal residual disease (MRD) negative status using the IMWG criteria [Up to Approximately 104 Weeks]
Phase 1 and phase 2
- Overall survival (OS) [Up to Approximately 104 Weeks]
Phase 1 and phase 2
- Patient-reported Quality of Life (QOL) per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) [Up to 12 Weeks After the Last Dose]
Phase 1 and phase 2 The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social) , symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
- Patient-reported QOL per EORTC Quality of Life Questionnaire-Multiple Myeloma module 20 (EORTC QLQ-MY20) [Up to 12 Weeks After the Last Dose]
Phase 1 and phase 2 The EORTC QLQ-MY20 is a self-administered instrument to assess QoL in persons with MM. This 20-item questionnaire measures the following domains: symptom scales, including disease symptoms (6 items) and symptoms related to side effects of treatment (10 items); function scale and future perspective (3 items); and body image (1 item). A high score represents a high level of symptoms or problems.
- Patient-reported QOL per EuroQoL-5 Dimension-3 Level Scale (EQ-5D-3L) [Up to 12 Weeks After the Last Dose]
Phase 1 and phase 2 The EQ-5D-3L is a self-administered generic standardized health status measure, consisting of an EQ-5D descriptive system and an EQ visual analog scale. The EQ-5D-3L descriptive system assesses 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 3-level scale: no problems, some problems, and extreme problems. The EQ visual analog scale component is a vertical visual analog scale used by patients to rate their health.
- Change in patient-reported global health status/QOL per EORTC QLQ-C30 [Baseline up to 12 Weeks After the Last Dose]
Phase 1 and phase 2 The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social) , symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
- Time to definitive deterioration in patient-reported global health status/QOL per EORTC QLQ-C30 [Up to 12 Weeks After the Last Dose]
Phase 1 and phase 2 The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social) , symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
- Change in patient-reported general health status per EQ-5D-3L [Baseline up to 12 Weeks After the Last Dose]
Phase 1 and phase 2 The EQ-5D-3L is a self-administered generic standardized health status measure, consisting of an EQ-5D descriptive system and an EQ visual analog scale. The EQ-5D-3L descriptive system assesses 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 3-level scale: no problems, some problems, and extreme problems. The EQ visual analog scale component is a vertical visual analog scale used by patients to rate their health.
- ORR as measured using the IMWG criteria [Up to Approximately 104 Weeks]
Phase 1 Only
- Incidence and severity of TEAEs during REGN5459 treatment period [Up to 12 Weeks After the Last Dose]
Phase 2 Only
- Incidence and severity of AESI during REGN5459 treatment period [Up to 12 Weeks After the Last Dose]
Phase 2 Only
Eligibility Criteria
Criteria
Key Inclusion Criteria:
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤1
-
Patients must have myeloma that is response-evaluable according to the 2016 International Myeloma Working Group (IMWG) response criteria
-
Measurable disease is defined as 1 or more of the following:
-
Serum M-protein ≥1 g/dL,
-
Urine M-protein ≥200 mg/24-hour, and/or
-
Free light chain (FLC) assay with involved FLC level ≥10 mg/dL with an abnormal serum FLC ratio
-
A patient with Immunoglobulin A (IgA) myeloma but without measurable M-protein may be enrolled if quantitative IgA levels are ≥400 mg/dL and can be followed longitudinally
-
A patient with non-secretory MM may be considered for enrollment after discussion with the sponsor that includes the feasibility of an individualized plan for response assessment
-
Patients with MM who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease, or intolerance of the therapy, and including either:
-
Progression on or after at least 3 lines of therapy, or intolerance of therapy, including a proteasome inhibitor, an Immunomodulatory imide drug (IMiD), and an anti-CD38 antibody, OR
-
Progression on or after an anti-CD38 antibody and having disease that is "double refractory" to a proteasome inhibitor and an IMiD, or intolerance of therapy. The anti-CD38 antibody may have been administered alone or in combination with another agent such as a proteasome inhibitor. Refractory disease is defined as lack of response or relapse within 60 days of last treatment.
- Adequate hematologic function as measured by:
-
Platelet count > 50 x 109/L. A patient may not have received a platelet transfusion within 7 days to meet this platelet eligibility requirement.
-
ANC > 1.0 x 109/L. A patient may not have received granulocyte colony stimulating factor (G-CSF) within 2 days to meet this absolute neutrophil count eligibility requirement.
-
Hemoglobin > 8.0 g/dL
- Adequate hepatic function, defined as:
-
Total bilirubin ≤1.5 x ULN
-
Transaminase (ALT, AST) ≤2.5 x ULN
-
Alkaline phosphatase ≤2.5 x ULN
- Patients with Gilbert syndrome do not need to meet this total bilirubin requirement provided that the total bilirubin is unchanged from the baseline value.
- Serum creatinine clearance by Cockcroft-Gault >30 mL/min
-
A patient with a creatinine clearance by Cockcroft-Gault who does not meet eligibility criteria may be considered for enrollment if a measured creatinine clearance (based on 24-hour urine collection or other reliable method) is >30 mL/min
-
Life expectancy of at least 6 months
Key Exclusion Criteria:
-
Patients with known MM brain lesions or meningeal involvement
-
History of neurodegenerative condition or central nervous system (CNS) movement disorder, or patients with a history of seizure within 12 months before study enrollment are excluded
-
Cardiac ejection fraction <40% by echocardiogram or multi-gated acquisition scan (MUGA)
-
Prior treatment with any anti-BCMA antibody (including antibody-drug conjugate or bispecific antibody) or BCMA-directed CAR T therapy
-
Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; or other uncontrolled infection
-
Patients with HIV who have controlled infection (undetectable viral load and CD4 count above 350 cells/microliter either spontaneously or on a stable antiviral regimen) are permitted.
-
Patients with hepatitis B (Hepatitis B Surface Antigen Test positive [HepBsAg+]) who have controlled infection (serum HBV DNA polymerase chain reaction [PCR] that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted.
-
Patients who are HCV antibody-positive (HCV Ab+) who have controlled infection (undetectable HCV RNA by polymerase chain reaction (PCR) either spontaneously or in response to a successful prior course of anti-HCV therapy) are permitted.
- History of allogeneic stem cell transplantation at any time, or autologous stem cell transplantation within 12 weeks of the start of study treatment
NOTE: Other protocol defined Inclusion/Exclusion Criteria apply.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Regeneron Study Site | Indianapolis | Indiana | United States | 46202 |
| 2 | Regeneron Study Site | Ann Arbor | Michigan | United States | 48109 |
| 3 | Regeneron Study Site | Rochester | Minnesota | United States | 55905 |
| 4 | Regeneron Study Site | New York | New York | United States | 10029 |
| 5 | Regeneron Study Site | Dallas | Texas | United States | 75390 |
| 6 | Regeneron Study Site | Houston | Texas | United States | 77030 |
| 7 | Regeneron Study Site | Milwaukee | Wisconsin | United States | 53226 |
Sponsors and Collaborators
- Regeneron Pharmaceuticals
Investigators
- Study Director: Clinical Trials Investigator, Regeneron Pharmaceuticals
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- R5459-ONC-1888
- 2019-001108-39